Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven medulloblastoma or supratentorial primitive neuroectodermal tumor~* Average-risk group:~  * Localized tumor with no overt evidence of invasion beyond the posterior fossa~ * Less than 1.5 cm2 residual tumor/imaging abnormality~ * No CNS or extraneural metastasis (confirmed by bone scan)~ * Brain stem invasion allowed if above criteria met~* High-risk group:~  * Metastatic disease within the neuraxis (subarachnoid dissemination) OR greater than 1.5 cm\^2 residual disease at the primary site after surgery~* No bone involvement by bone scan~* Must begin study within 28 days of definitive surgery~PATIENT CHARACTERISTICS:~Age~* 3 to 20 at diagnosis~Performance status~* ECOG 0-3 (except patients with posterior fossa syndrome)~Life expectancy~* Not specified~Hematopoietic~* WBC greater than 3,000/mm\^3~* Absolute neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3~* Hemoglobin greater than 10 g/dL~Hepatic~* Bilirubin less than 1.5 mg/dL~* SGPT less than 1.5 times normal~Renal~* Creatinine less than 1.2 mg/dL OR~* Creatinine clearance greater than 70 mL/min~Other~* Not pregnant or nursing~* Negative pregnancy test~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Prior corticosteroids allowed~Radiotherapy~* No prior radiotherapy~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Average-risk (Type: EXPERIMENTAL): Participants meeting the eligibility requirements for assignment to the average-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy.
- High-risk (Type: EXPERIMENTAL): Participants meeting the eligibility requirements for assignment to the high-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).